Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Dec 30;42(1):9.
doi: 10.1007/s10585-024-10327-w.

Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study

Alessandro Rizzo  1 , Fernando Sabino Marques Monteiro  2   3 , Veronica Mollica  4 , Oronzo Brunetti  5 , Elsa Vitale  6 , Angela Monica Sciacovelli  5 , Andrey Soares  2   7 , Francesco Massari  4   8 , Matteo Santoni  9
Affiliations
Meta-Analysis

Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study

Alessandro Rizzo et al. Clin Exp Metastasis. .

Abstract

Immune-based combinations have significantly improved the treatment of metastatic renal cell carcinoma (mRCC); however, immunotherapy has reported varying degrees of efficacy across different metastatic sites, with liver and bone metastases traditionally considered more challenging to treat. In MOUSEION-08 study, we aimed to investigate the association between lung, liver, and bone metastases and clinical outcomes such as Overall Survival (OS) and Progression- Free Survival (PFS) in mRCC patients receiving immune-based combinations. The present systematic review and study-level meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA). PFS and OS were measured as Hazard Ratios (HRs) and 95% confidence intervals (CIs). The protocol was registered with PROSPERO, Registration number: CRD42024581488. Our search resulted in the identification of 2364 potentially relevant reports, which were subsequently restricted to three. The pooled HRs for OS and PFS in patients with lung metastases receiving immune-based combinations versus sunitinib were 0.61 (95% CI, 0.51-0.72) and 0.47 (95% CI, 0.38-0.59), respectively. In patients with liver metastases, the pooled HRs for OS and PFS were 0.56 (95% CI, 0.42-0.75) and 0.48 (95% CI, 0.34-0.67), while the pooled HRs for OS and PFS in patients with bone metastases were 0.64 (95% CI, 0.49-0.84) and 0.36 (95% CI, 0.27-0.49), respectively. According to our findings, the analyses reported similar HRs for OS and PFS, something that further underlines the role of immune-based combinations in this setting, regardless of metastatic sites, such as lung, liver, and bone metastases. Ongoing research and clinical trials are destined to refine and improve immunotherapeutic strategies for mRCC, aiming to enhance efficacy across all metastatic sites and to define predictive biomarkers.

Keywords: Bone metastases; Immune-based combinations; Immunotherapy; Liver metastases; Lung metastases; Renal cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Choueiri TK et al (2018) Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med
    1. Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, Schuettfort VM, Laukhtina E, Egawa S, Fajkovic H, Remzi M, Shariat SF, Schmidinger M (2021) First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network Meta-analysis. Eur Urol Oncol 4(5):755–765. https://doi.org/10.1016/j.euo.2021.03.001 Epub 2021 Mar 20. PMID: 33757737 - DOI - PubMed
    1. Dudani S, de Velasco G, Wells JC, Gan CL, Donskov F, Porta C, Fraccon A, Pasini F, Lee JL, Hansen A, Bjarnason GA, Beuselinck B, Pal SK, Yuasa T, Kroeger N, Kanesvaran R, Reaume MN, Canil C, Choueiri TK, Heng DYC (2021) Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association with Survival. JAMA Netw Open 4(1):e2021869. https://doi.org/10.1001/jamanetworkopen.2020.21869 . PMID: 33475752; PMCID: PMC7821027 - DOI - PubMed - PMC
    1. Massari F, Di Nunno V, Guida A, Costa Silva CA, Derosa L, Mollica V, Colomba E, Brandi G, Albiges L (2021) Addition of primary metastatic site on bone, brain, and liver to IMDC Criteria in patients with metastatic renal cell carcinoma: a validation study. Clin Genitourin Cancer 19(1):32–40 Epub 2020 Jun 27. PMID: 32694008 - DOI - PubMed
    1. Singla A, Sharma U, Makkar A, Masood PF, Goel HK, Sood R, Ahuja A, Singh R (2022) Rare metastatic sites of renal cell carcinoma: a case series. Pan Afr Med J 42:26. https://doi.org/10.11604/pamj.2022.42.26.33578 . PMID: 35910051; PMCID: PMC9288148 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources